Neogen Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Neogen (NEOG)

An FDA warning over the recalled HYCOAT equine product cut as much as 7.22% from NEOG in a single session. The investigation concerns whether Neogen investors were adequately informed of Neogen Vet product-quality risks before the news reached the market.

NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) stock plummeted after an FDA warning concerning the recalled Neogen Vet product HYCOAT sent shares down as much as 7.22%. If you owned NEOG when that warning hit the market, you may have legal rights. Investors who lost money are encouraged to submit their loss details now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

HYCOAT was marketed as sterile. FDA testing reportedly identified multiple fungal species in the product, and coverage of the warning cited nearly 100 affected horses and at least 20 horse deaths.

The decline came before any earnings report. Neogen's next quarterly results are not scheduled until October 6, 2026. Levi & Korsinsky is investigating potential securities law violations on behalf of Neogen shareholders who suffered losses, including those who have since sold their shares.

Neogen shareholders who suffered a loss can request a review of their NEOG losses or call (212) 363-7500.

Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

Frequently Asked Questions About the NEOG Investigation

Q: How much did NEOG stock drop?A: Shares fell as much as approximately 7.22% intraday after an FDA warning concerning the recalled Neogen Vet product HYCOAT, which reporting tied to fungal contamination, nearly 100 affected horses, and at least 20 horse deaths. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether Neogen made materially false or misleading statements about the quality, supply, and performance of its Animal Safety products, including the Neogen Vet product line. When the FDA warning concerning the recalled HYCOAT product became public, the stock price declined.

Q: When did Neogen allegedly mislead investors?A: The investigation concerns statements made before the FDA warning regarding HYCOAT that allegedly caused investors to purchase securities at inflated prices.

Q: What do NEOG investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my NEOG shares -- can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought NEOG and sold at a loss may still participate in the investigation.

Q: What if my NEOG losses are small -- is it still worth contacting a lawyer?A: Yes. There is no minimum loss amount required to participate in the investigation.

Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE Levi & Korsinsky, LLP